Latest Ratios: P/E Ratio -1.8x · EV/EBITDA 10.4x · ROE N/A. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $539M | $703M | — | — | — | — | — | — |
| Enterprise Value | $5.2B | $5.3B | — | — | — | — | — | — |
| P/E Ratio → | -1.83 | — | — | — | — | — | — | — |
| P/S Ratio | 0.56 | 0.73 | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | 4.59 | 5.99 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.51 | — | — | — | — | — | — |
| EV / EBITDA | 10.44 | 10.78 | — | — | — | — | — | — |
| EV / EBIT | 114.40 | 197.05 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 27.6% | 27.6% | 74.3% | 75.5% | 81.1% | 84.3% | 66.0% | 84.8% |
| Operating Margin | 4.7% | 4.7% | -149.4% | 16.8% | -33.6% | 34.5% | -14.1% | 37.5% |
| Net Profit Margin | -29.4% | -29.4% | -176.9% | -9.5% | -53.1% | 9.1% | -55.5% | 1.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -183.6% | -5.2% | -27.7% | 4.2% | -22.9% | 0.5% |
| ROA | -5.7% | -5.7% | -27.2% | -1.3% | -7.3% | 1.2% | -6.3% | 0.1% |
| ROIC | 0.7% | 0.7% | -19.3% | 2.0% | -4.1% | 4.1% | -1.4% | 3.7% |
| ROCE | 0.9% | 0.9% | -23.7% | 2.3% | -4.7% | 4.8% | -1.6% | 4.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 54.05 | 2.67 | 2.67 | 2.10 | 1.80 | 2.74 |
| Debt / EBITDA | 9.39 | 9.39 | — | 7.77 | 90.36 | 6.17 | 16.97 | 7.07 |
| Net Debt / Equity | — | — | 53.85 | 2.63 | 2.48 | 2.02 | 1.75 | 2.72 |
| Net Debt / EBITDA | 9.35 | 9.35 | — | 7.65 | 84.05 | 5.94 | 16.50 | 7.04 |
| Debt / FCF | — | — | — | 71.52 | 15.74 | 14.81 | 14.63 | 24.82 |
| Interest Coverage | 0.07 | 0.07 | -4.43 | 0.68 | -0.85 | 1.51 | -0.63 | 1.03 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.86 | 0.86 | 0.82 | 1.16 | 2.54 | 2.25 | 1.86 | 1.35 |
| Quick Ratio | 0.86 | 0.86 | 0.82 | 1.16 | 2.54 | 2.25 | 1.86 | 1.35 |
| Cash Ratio | 0.06 | 0.06 | 0.08 | 0.43 | 1.90 | 1.31 | 1.13 | 0.25 |
| Asset Turnover | — | 0.20 | 0.18 | 0.14 | 0.15 | 0.14 | 0.11 | 0.12 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 52.24 | 43.77 | 32.17 | 26.67 | 32.63 | 24.60 | 28.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $16M | $16M | $16M | $16M | $16M | $12M | $28M |
Insolvency and debt overhang
According to recent market data, Claritev trades at a P/S ratio of 0.59, a valuation level that suggests investors are heavily discounting the company's future growth prospects and questioning the long-term viability of its legacy out-of-network repricing model in the face of evolving regulatory pressures.
The current EV/EBITDA multiple of 10.50 appears to price the company as a declining asset rather than a high-growth data analytics firm. This valuation gap implies that the market remains skeptical of management's ability to successfully transition the business toward higher-margin decision science services.
Based on reported financial statements, Claritev's ROIC has trended toward near-zero levels, reaching 0.1% in 2026Q1, which indicates that the company is failing to generate meaningful returns on its invested capital compared to the cost of its significant debt obligations.
The persistent decay in ROIC suggests that the company's capital allocation strategy has been value-destructive, likely exacerbated by the heavy amortization of intangible assets from past acquisitions. Investors should monitor whether future investments in AI-driven analytics can reverse this trend or if the capital base remains trapped in low-return legacy infrastructure.
As evidenced by the company's financial disclosures, Claritev's DSO has fluctuated between 29 and 53 days over the last ten quarters, highlighting the inherent volatility in collecting transactional revenue from large commercial payers within a complex, dispute-prone healthcare reimbursement environment.
The lack of consistent improvement in the cash conversion cycle suggests that the company lacks significant leverage over its payer base, leading to lumpy cash inflows. This inefficiency forces the company to maintain higher liquidity buffers than would otherwise be necessary for a mature data-services provider.
Data from recent filings indicates that Claritev's debt-to-EBITDA ratio has remained elevated, consistently exceeding 35x in recent quarters, which leaves the company with virtually no margin for operational error and severely restricts its capacity to fund necessary R&D for its strategic pivot.
The interest coverage ratio, which has frequently dipped into negative territory, suggests that the company's ability to service its debt is entirely dependent on maintaining stable claim volumes. Any further contraction in the out-of-network market could trigger a liquidity crisis, given the company's limited cash reserves.
As reported in financial statements, the market's reliance on EBITDA as a primary valuation metric for Claritev is fundamentally flawed, as it ignores the massive non-cash amortization of intangible assets that masks the company's inability to generate sustainable free cash flow from its core operations.
Investors should prioritize free cash flow and net income metrics, as EBITDA fails to account for the capital-intensive nature of maintaining the company's legacy PPO network. Relying on EBITDA likely leads to an overestimation of the company's underlying earning power and a misunderstanding of its true financial health.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTEV stock.
Claritev Corporation's current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
Claritev Corporation's current EV/EBITDA is 10.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.8x.
Based on historical data, Claritev Corporation is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Claritev Corporation has 27.6% gross margin and 4.7% operating margin.
Claritev Corporation's Debt/EBITDA ratio is 9.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.